ALZN · Alzamend Neuro, Inc.
$1.33
+0.07 (+5.56%)
At close · Jul 24
Going-concern doubt
— flagged Jul 22, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our audited financial statements are issued.”View the 10-K filed Jul 22, 2026
Market Cap
$6.37M
Shares
4.79M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$8.77M
-94.3%
FY2026
Diluted EPS
-$2.63
+76.8%
FY2026
Operating Cash Flow
-$8.07M
-22.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | — | — | $1706 | $1706 | |
| $3.63M | $1.41M | $6.46M | $7.45M | $5.2M | $1.31M | |
| $5.14M | $3.08M | $3.48M | $7.42M | $7.12M | $3.64M | |
| $8.77M | $4.5M | $9.94M | — | — | — | |
| — | — | — | $14.87M | $12.32M | $4.95M | |
| -$8.77M | -$4.5M | -$9.94M | -$14.87M | -$12.32M | -$4.95M | |
| $6619 | $18.03K | $10.1K | $7701 | $46.52K | $142.42K | |
| $1078 | — | — | — | — | — | |
| -$5541 | -$18.03K | -$10.1K | -$7701 | -$42.52K | -$94.68K | |
| -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | |
| -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | |
| -$8.77M | -$5.11M | — | — | — | — | |
| USD/shares | -$2.63 | -$11.32 | -$132.30 | -$202.50 | — | — |
| USD/shares | -$2.63 | -$11.32 | -$132.30 | -$202.50 | — | — |
| shares | 3.34M | 450.8K | 75.17K | 72.24K | 66K | 53.81K |
| shares | 3.34M | 450.8K | 75.17K | 72.24K | — | 53.81K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×